BioStem Technologies, Inc.
BSEMHealthcareNASDAQBiotechnology · Last scanned Oct 17, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 16
Part of the healthcare sector, BioStem Technologies, Inc. (BSEM) is listed under Biotechnology. The company carries a $39.0M market cap, placing it firmly in the micro-cap category. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.
Market Cap
$39.0M
Beta
0.50
P/E (TTM)
2.38
P/E (Fwd)
7.21
EPS (TTM)
$0.88
EPS (Fwd)
$0.29
ROE
-74.7%
ROA
-18.1%
Cash
$7.0M
Total Debt
$1.2M
Free CF
$8.7M
52W Change
-61.5%
Annual Financials
Cash vs Debt
Where BSEM stands vs its 150-day and 200-day moving averages
As of the October 17, 2026 close, BSEM finished 47.09% below its 150-day moving average ($3.95) and 51.95% below its 200-day moving average ($4.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BSEM overbought or oversold?
At the October 17, 2026 close, BSEM's RSI(14) was 12.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $7.0M in cash comfortably exceeding the $1.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $8.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -74.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $4.3M (2021) to $301.8M (2024), reflecting a 6853% increase over the period.
BSEM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing BSEM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.